Bg pattern

SUNLENCA 464 mg INJECTABLE SOLUTION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

5.0 (197)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use SUNLENCA 464 mg INJECTABLE SOLUTION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

Sunlenca 464 mg Solution for Injection

lenacapavir

This medicine is subject to additional monitoring, which will allow for the quick identification of new safety information. You can help by reporting any side effects you may get. The last section of section 4 will tell you how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Sunlenca and what is it used for
  2. What you need to know before you are given Sunlenca
  3. How Sunlenca is given
  4. Possible side effects
  5. Storage of Sunlenca
  6. Contents of the pack and other information

1. What is Sunlenca and what is it used for

Sunlenca contains the active substance lenacapavir. It is an antiretroviral medicine known as a capsid inhibitor.

Sunlenca is a long-acting medicine and is used in combination with other antiretroviral medicinesto treat human immunodeficiency virus type 1 (HIV-1), the virus that causes acquired immune deficiency syndrome (AIDS).

It is used to treat HIV-1 infection in adults with limited treatment options (for example, when other antiretroviral medicines are not effective enough or are not suitable).

Treatment with Sunlenca in combination with other antiretrovirals reduces the amount of HIV in the body. This will improve the function of the immune system (the body's natural defenses) and reduce the risk of developing illnesses associated with HIV infection.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you are given Sunlenca

Do not receive Sunlenca

  • If you are allergic to lenacapavir or any of the other ingredients of this medicine (listed in section 6).
  • If you are taking any of the following medicines:
    • rifampicin, used to treat some bacterial infections such as tuberculosis
    • carbamazepine, phenytoin, used to prevent seizures
    • St. John's Wort (Hypericum perforatum), a herbal medicine used for depression and anxiety

If you think this applies to you, do not receive Sunlenca and tell your doctor immediately.

Warnings and precautions

Talk to your doctor before using Sunlenca

  • Talk to your doctor or pharmacist if you have or have ever had severe liver disease or if tests have shown liver problems. Your doctor will carefully consider whether to treat you with Sunlenca.

While you are using Sunlenca

Once you start using Sunlenca, be aware of:

  • Signs of inflammation or infection.

If you notice any of these symptoms, tell your doctor immediately.For more information, see section 4, Possible side effects.

Regular appointments are important

It is important that you attend your scheduled appointmentsto receive the Sunlenca injection to control HIV infection and prevent your disease from getting worse. Talk to your doctor if you are considering stopping treatment. If there is a delay in giving you your injection or if you stop receiving Sunlenca, you will need to take other medicines to treat HIV infection and reduce the risk of developing viral resistance.

Children and adolescents

Do not give this medicine to children under 18 years of age. The use of Sunlenca in patients under 18 years of age has not been studied yet, so it is not known how safe and effective the medicine is in this age group.

Other medicines and Sunlenca

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Sunlenca may interact with other medicines. This can prevent Sunlenca or other medicines from working properly or can increase the risk of side effects. In some cases, your doctor may need to adjust the dose or check your blood levels.

Medicines that must not be taken with Sunlenca:

  • rifampicin, used to treat some bacterial infections such as tuberculosis
  • carbamazepine, phenytoin, used to prevent seizures
  • St. John's Wort (Hypericum perforatum), a herbal medicine used for depression and anxiety

If you are taking any of these medicines, do not receive Sunlenca injection and tell your doctor immediately.

Tell your doctor especially if you are taking:

  • antibiotics that contain:
    • rifabutin
  • antiepileptics, used to treat epilepsy and prevent seizures (convulsions), that contain:
    • oxcarbazepine or phenobarbital
  • medicines used to treat HIV, that contain:
    • atazanavir/cobicistat, efavirenz, nevirapine, tipranavir/ritonavir or etravirine
  • medicines used to treat migraine headaches, that contain:
    • dihydroergotamine or ergotamine
  • medicines used to treat impotence and pulmonary hypertension, that contain:
    • sildenafil or tadalafil
  • medicines used to treat impotence, that contain:
    • vardenafil
  • corticosteroids (also known as “steroids”) given by mouth or by injection, used to treat allergies, inflammatory bowel diseases and other diseases that involve inflammation in the body, that contain:
    • dexamethasone or hydrocortisone/cortisone
  • medicines used to lower cholesterol, that contain:
    • lovastatin or simvastatin
  • antiarrhythmics used to treat heart problems, that contain:
    • digoxin
  • medicines used to help you sleep, that contain:
    • midazolam or triazolam
  • anticoagulants used to prevent and treat blood clots, that contain:
    • rivaroxaban, dabigatran or edoxaban

Tell your doctor if you are taking any of these medicinesor if you start taking any of these medicines during treatment with Sunlenca. Do not stop your treatment without talking to your doctor.

Sunlenca is a long-acting medicine. You should know that if you decide to stop or change your treatment to another one after talking to your doctor, low levels of lenacapavir (the active substance of Sunlenca) may remain in your body for several months after your last injection. It is not expected that the presence of these low levels will affect other antiretroviral medicines you may take later to treat HIV infection. However, the presence of low levels of lenacapavir in your body may affect other medicines you take in the 9 months following your last Sunlenca injection. Ask your doctor if these medicines are safe for you after stopping treatment with Sunlenca.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

As a precaution, you should avoid using Sunlenca during pregnancy unless your doctor tells you otherwise.

Women with HIV-1 infection should not breast-feed their babies, as HIV-1 can be passed to the baby through breast milk. If you are breast-feeding or think you may want to breast-feed, talk to your doctor as soon as possible.

Driving and using machines

Sunlenca is not expected to affect your ability to drive or use machines.

Sunlenca contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per injection; this is, essentially “sodium-free”.

3. How Sunlenca is given

Sunlenca is used in combination with other antiretroviral medicinesto treat HIV infection. Your doctor will tell you which other medicines you should take to treat HIV infection and when you should take them.

Treatment with Sunlenca starts with taking tablets by mouth, followed by injections given by your doctor or nurse, as described below.

Talk to your doctor before taking the tablets.The doctor will tell you when to start taking the tablets and when to schedule your appointment to receive the first injections.

Day 1 of treatment:

  • Two tablets by mouth. These can be taken with or without food.

Day 2 of treatment:

  • Two tablets by mouth. These can be taken with or without food.

Day 8 of treatment:

  • One tablet by mouth. This can be taken with or without food.

Day 15 of treatment:

  • Two injections in the abdomen (belly) given at the same time by your doctor or nurse.

Every 6 months:

  • Two injections in the abdomen given at the same time by your doctor or nurse.

If you are given more Sunlenca injection than you should

Your doctor or nurse will give you this medicine, so it is unlikely that you will be given too much. Tell your doctor or nurse if you are concerned.

If you miss a Sunlenca injection

  • It is important that you attend your scheduled appointments every 6 months to receive the Sunlenca injections. This will help control HIV infection and prevent your disease from getting worse.
  • If you think you will not be able to attend your appointment to receive the injections, call your doctor as soon as possible to discuss your treatment options.

Read the package leaflet of Sunlenca tablets if you miss a dose or vomit after taking the tablets.

If you stop treatment with Sunlenca

Do not stop treatment with Sunlenca without talking to your doctor. Continue treatment with Sunlenca injections as long as your doctor recommends. Stopping Sunlenca may seriously affect the effectiveness of future treatments for HIV.

Talk to your doctor if you want to stop treatment with Sunlenca injections.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Serious side effects: tell a doctor immediately

  • Any sign of inflammation or infection. In some patients with advanced HIV infection (AIDS) and a history of opportunistic infections (infections that occur in people with a weakened immune system), signs and symptoms of inflammation due to previous infections may occur shortly after starting HIV treatment. These symptoms are thought to be due to an improvement in the body's immune response, which enables it to fight off infections that may have been present without obvious symptoms.
  • Autoimmune disorders, where the immune system attacks the body's healthy tissues, can also occur after starting HIV treatment. Autoimmune disorders may occur many months after starting treatment. Be aware of any symptoms of infection or other symptoms, such as:
    • muscle weakness
    • weakness of the body that starts in the hands and feet and moves towards the trunk
    • palpitations, tremors or hyperactivity

If you notice any of these symptoms or any symptoms of inflammation or infection, tell your doctor immediately.

Very common side effects

(may affect more than 1 in 10 people)

  • Reactions at the Sunlenca injection site.

Symptoms may include:

  • pain and discomfort
  • a lump or hardened mass
  • inflammatory reaction such as redness, itching and swelling

Common side effects

(may affect up to 1 in 10 people)

  • Nausea

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist, even if they are not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Sunlenca

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the vial label and carton after {EXP}. The expiry date is the last day of the month shown.

This medicine does not require any special storage conditions. Keep the vial in the original packaging to protect it from light.

6. Container Contents and Additional Information

Sunlenca Composition

The active ingredient is lenacapavir. Each single-dose vial contains 463.5 mg of lenacapavir.

The other components are

Macrogol (E1521), water for injectable preparations.

Appearance of Sunlenca and Container Contents

Sunlenca injectable solution is a clear, yellow to brown solution without visible particles. Sunlenca is presented in two glass vials containing 1.5 ml of injectable solution each. These vials are included in an administration kit that also contains 2 vial access devices (a device that will allow your doctor or nurse to extract Sunlenca from the vial), 2 disposable syringes, and 2 injection needles.

Marketing Authorization Holder

Gilead Sciences Ireland UC

Carrigtohill

County Cork, T45 DP77

Ireland

Manufacturer

Gilead Sciences Ireland UC

IDA Business & Technology Park

Carrigtohill

County Cork

Ireland

You can request more information about this medication by contacting the local representative of the marketing authorization holder:

Belgium

Gilead Sciences Belgium SRL-BV

Tel: + 32 (0) 24 01 35 50

Lithuania

Gilead Sciences Poland Sp. z o.o.

Tel.: + 48 22 262 8702

Greece

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Luxembourg

Gilead Sciences Belgium SRL-BV

Tel: + 32 (0) 24 01 35 50

Czech Republic

Gilead Sciences s.r.o.

Tel: + 420 910 871 986

Hungary

Gilead Sciences Ireland UC

Tel.: + 353 (0) 1 686 1888

Denmark

Gilead Sciences Sweden AB

Tlf: + 46 (0) 8 5057 1849

Malta

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Germany

Gilead Sciences GmbH

Tel: + 49 (0) 89 899890-0

Netherlands

Gilead Sciences Netherlands B.V.

Tel: + 31 (0) 20 718 36 98

Estonia

Gilead Sciences Poland Sp. z o.o.

Tel.: +48 22 262 8702

Norway

Gilead Sciences Sweden AB

Tlf: + 46 (0) 8 5057 1849

Greece

Gilead Sciences Ελλάς Μ.ΕΠΕ.

Tel: + 30 210 8930 100

Austria

Gilead Sciences GesmbH

Tel: + 43 1 260 830

Spain

Gilead Sciences, S.L.

Tel: + 34 91 378 98 30

Poland

Gilead Sciences Poland Sp. z o.o.

Tel.: + 48 22 262 8702

France

Gilead Sciences

Tel: + 33 (0) 1 46 09 41 00

Portugal

Gilead Sciences, Lda.

Tel: + 351 21 7928790

Croatia

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Romania

Gilead Sciences (GSR) S.R.L.

Tel: + 40 31 631 18 00

Ireland

Gilead Sciences Ireland UC

Tel: + 353 (0) 214 825 999

Slovenia

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Iceland

Gilead Sciences Sweden AB

Sími: + 46 (0) 8 5057 1849

Slovakia

Gilead Sciences Slovakia s.r.o.

Tel: + 421 232 121 210

Italy

Gilead Sciences S.r.l.

Tel: + 39 02 439201

Finland

Gilead Sciences Sweden AB

Tel: + 46 (0) 8 5057 1849

Cyprus

Gilead Sciences Ελλάς Μ.ΕΠΕ.

Tel: + 30 210 8930 100

Sweden

Gilead Sciences Sweden AB

Tel: + 46 (0) 8 5057 1849

Latvia

Gilead Sciences Poland Sp. z o.o.

Tel.: + 48 22 262 8702

United Kingdom (Northern Ireland)

Gilead Sciences Ireland UC

Tel: + 44 (0) 8000 113 700

Date of Last Revision of this Prospectus:

Detailed information on this medication is available on the European Medicines Agency website: http://www.ema.europa.eu.

-----------------------------------------------------------------------------

This information is intended solely for healthcare professionals:

Instructions for Use - Sunlenca 464 mg Injectable Solution

The Kit Contains

2 vials

Clear glass vial with yellow liquid and black sealed cap

2 vial access devices

Green adapter with circular base and white top with sealing ring

2 syringes

Transparent syringe with black plunger and numerical graduations marked along the cylinder

2 injection needles

Hypodermic needle with angled bevel showing sharp tip and light gray cylindrical body

All components are for single use.

Two 1.5 ml injectionsare required for a complete dose. It is necessary to use the vial access device.

Check that:

  • The vial contains a yellow to brown solution without visible particles
  • The contents are not damaged
  • The medication has not expired
  1. Prepare the vial

Vial with yellow liquid and black cap being held by a hand with a blue arrow pointing upwards

Remove the cap.

Glass vial with yellow liquid and a needle inserted into the cap held by a gloved hand

Clean the vial seal with an alcohol swab.

  1. Prepare the vial access device

Yellow vial with liquid held by a hand and a green adapter in a vertical position with an arrow indicating downward direction

Push down.

Green adapter with slots and a hand rotating a blue cylinder over it with blue arrows indicating rotation

Turn to remove.

  1. Attach and fill the syringe

Syringe with a green safety device showing how to connect and disconnect the needle protector with blue arrows

  • Attach the syringe and inject 1.5 ml of air into the vial.
  • Turn upside down and withdraw all the contents.
  1. Prepare an injection site on the patient's abdomen

Human silhouette showing the abdomen with dark circles indicating possible injection sites

Possible injection sites (at a minimum of 5 cm from the navel)

  1. Attach the needle and syringe

Hand holding yellow syringe with medication turning the blue plunger clockwise

Attach the injection needle and fill 1.5 ml.

  1. Inject the dose

Hand injecting medication with syringe into the skin, blue arrow indicating direction of needle insertion and yellow liquid in the plunger

Inject 1.5 ml of Sunlenca subcutaneously

  1. Administer the second injection

Blue circle with curved arrows indicating a rotational movement in a clockwise direction within a white square

Repeat the steps for the 2nd injection in a new injection site.

Online doctors for SUNLENCA 464 mg INJECTABLE SOLUTION

Discuss questions about SUNLENCA 464 mg INJECTABLE SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (100)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

5.0 (97)
Doctor

Jorge Correa Bellido

General medicine 7 years exp.

Dr. Jorge Correa Bellido is a Spanish physician who offers online consultations in Spanish and English. He graduated from the University of La Laguna and has a solid background in clinical practice and international research.

Throughout his career, he has participated in various medical and academic projects, including a research fellowship in Spain, where he contributed to evidence-based studies in the field of family medicine. This experience allowed him to broaden his global perspective on healthcare and comprehensive patient care.

Dr. Correa Bellido has worked with several healthcare providers in Spain, focusing particularly on patient-centered care and public health initiatives aimed at communities with limited access to healthcare services.

In addition, he actively participates in international medical conferences and workshops, which allows him to stay up to date with the latest medical advances and collaborate with healthcare professionals from different countries.

Dr. Correa Bellido provides comprehensive care for a wide variety of medical conditions, including:

  • respiratory infections
  • gastrointestinal disorders
  • cardiovascular problems
  • endocrine and metabolic diseases
  • musculoskeletal and dermatological conditions
  • as well as mental health conditions such as anxiety and depression.

He also treats infectious and allergic diseases, general health concerns, and provides guidance on prevention and healthy lifestyle habits.

His services include virtual consultations, diagnosis and management of acute and chronic diseases, prescription renewals, and personalized medical advice.

With a patient-centered approach and a strong commitment to continuous learning, Dr. Correa Bellido provides accessible and high-quality healthcare to patients both in Spain and around the world.

0.0 (10)
Doctor

Lizaveta Trafimchuk Takhvaniuk

Dermatology 10 years exp.

Dr. Lizaveta Trafimchuk Takhvaniuk graduated in Medicine and subsequently specialized in Dermatology and Venereology. She has more than 10 years of clinical experience and is licensed to practice in Spain, where she focuses on the comprehensive diagnosis and treatment of dermatological conditions.

Throughout her education and professional career, Dr. Trafimchuk has gained extensive experience in managing diseases of the skin, hair, and nails, as well as in the diagnosis, treatment, and prevention of sexually transmitted infections (STIs). Her clinical approach is based on evidence-based medicine, combined with personalized care tailored to each patient’s needs.

In her daily practice, she treats a wide range of dermatological conditions, including chronic inflammatory dermatoses such as acne, rosacea, atopic dermatitis, psoriasis, and eczema. She also has experience in treating pigmentation disorders, including melasma, post-inflammatory hyperpigmentation, and dyschromia.

She has developed a particular interest in trichology, treating various types of alopecia, chronic hair loss, and scalp disorders. In addition, she has experience in managing infectious dermatoses of fungal, viral, and bacterial origin, as well as in evaluating benign and suspicious skin lesions, with referral to specialized care when necessary.

With a strong interest in a comprehensive approach to skin health, she also treats scars, post-procedural skin changes, and conditions related to hormonal factors and aging, including those associated with pregnancy, menopause, and age-related skin changes.

Thanks to her experience and continuous professional development, Dr. Trafimchuk provides high-quality medical care that is professional, confidential, and aligned with modern dermatology standards.

5.0 (197)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

4.6 (76)
Doctor

Anastasiia Shalko

Family medicine 13 years exp.

Dr. Anastasiia Shalko is a general practitioner with a background in both paediatrics and general medicine. She graduated from Bogomolets National Medical University in Kyiv and completed her paediatric internship at the P.L. Shupyk National Medical Academy of Postgraduate Education. After working as a paediatrician in Kyiv, she relocated to Spain, where she has been practising general medicine since 2015, providing care for both adults and children.Her work focuses on urgent, short-term medical concerns – situations where patients need quick guidance, symptom assessment and clear next steps. She helps people understand whether their symptoms require in-person evaluation, home management or a change in treatment. Common reasons for booking an online consultation include:

  • acute respiratory symptoms (cough, sore throat, runny nose, fever)
  • viral illnesses such as colds and seasonal infections
  • gastrointestinal complaints (nausea, diarrhoea, abdominal pain, gastroenteritis)
  • sudden changes in how a child or adult feels
  • questions about existing treatment and whether adjustments are needed
  • renewal of prescriptions when clinically appropriate

Dr. Shalko works specifically with urgent and short-term problems, providing practical recommendations and helping patients determine the safest next step. She explains symptoms clearly, guides patients through decision-making and offers straightforward medical advice for everyday acute issues.She does not provide long-term management of chronic conditions, ongoing follow-up or comprehensive care plans for complex long-term illnesses. Her consultations are designed for acute symptoms, sudden concerns and situations where timely medical input is important.With clinical experience in both paediatrics and general medicine, Dr. Shalko confidently supports adults and children. Her communication style is clear, simple and reassuring, helping patients feel informed and supported throughout the consultation.

5.0 (1225)
Doctor

Andrei Popov

General medicine 7 years exp.

Dr. Andrei Popov is a family physician with specialized training in the management of chronic pain. He provides video consultations for adults in Spain and across Europe: whether you have been living with pain for months that no one has been able to properly explain, or you need to resolve a health issue without waiting weeks for an appointment.

His approach is clear: to listen, organize your case, and provide you with a practical roadmap based on evidence-based medicine and adapted to your medical history and personal needs.

Pain: how he can help

  • Chronic pain (more than 3 months
  • Migraine and recurrent or high-intensity headaches
  •  Neck, lower back, back and joint pain
  •  Post-traumatic pain after injuries or surgeries
  •  Pain of neurological origin: neuralgia, neuropathic pain, fibromyalgia

General medicine

  • Frequent respiratory infections (cold, flu, persistent cough)
  • Hypertension, diabetes and metabolic disorders
  • Review of laboratory tests and MRI/CT reports (explained in clear language)
  • Preventive medicine and health monitoring
  • Second opinions and treatment adjustments (when clinically appropriate)

What the consultation is like
 Each session lasts up to 30 minutes. We review symptoms, medical history, medications and any tests you provide, and you finish the consultation with a clear treatment plan, defined next steps, and criteria to understand when follow-up may be needed. If warning signs are detected, he will clearly advise whether you need in-person care or urgent medical attention.

0.0 (0)
Doctor

Hocine Lokchiri

General medicine 21 years exp.

Dr. Hocine Lokchiri is a French consultant with over 20 years of experience in General and Emergency Medicine. He works with adults and children, helping patients with urgent symptoms, infections, sudden health changes and everyday medical concerns that require timely evaluation. His background includes clinical practice in France, Switzerland and the United Arab Emirates, which allows him to navigate different healthcare systems and manage a wide range of conditions with confidence. Patients value his calm, structured approach, clear explanations and evidence-based decision-making.

Online consultations with Dr. Lokchiri are suitable for many situations when someone needs quick medical guidance, reassurance or a clear next step. Common reasons for booking include:

  • fever, chills, fatigue and viral symptoms
  • cough, sore throat, nasal congestion, breathing discomfort
  • bronchitis and mild asthma flare-ups
  • nausea, diarrhoea, abdominal pain, digestive infections
  • rashes, allergic reactions, redness, insect bites
  • muscle or joint pain, mild injuries, sprains
  • headache, dizziness, migraine symptoms
  • stress-related symptoms, sleep disturbances
  • questions about test results and treatment plans
  • management of chronic conditions in stable phases
Many patients reach out when symptoms appear suddenly and cause concern, when a child becomes unwell unexpectedly, when a rash changes or spreads, or when it’s unclear whether an in-person examination is necessary. His emergency medicine background is particularly valuable online, helping patients understand risk levels, identify warning signs and choose safe next steps.

Some situations are not suitable for online care. If a patient has loss of consciousness, severe chest pain, uncontrolled bleeding, seizures, major trauma or symptoms suggesting a stroke or heart attack, he will advise seeking immediate local emergency services. This improves safety and ensures patients receive the right level of care.

Dr. Lokchiri’s professional training includes:

  • Advanced Trauma Life Support (ATLS)
  • Basic and Advanced Cardiac Life Support (BLS/ACLS)
  • Pediatric Advanced Life Support (PALS)
  • Prehospital Trauma Life Support (PHTLS)
  • eFAST and critical care transthoracic echocardiography
  • aviation medicine
He is an active member of several professional organisations, including the French Society of Emergency Medicine (SFMU), the French Association for Emergency Physicians (AMUF) and the Swiss Society of Emergency and Rescue Medicine (SGNOR). In consultations, he works with clarity and precision, helping patients understand their symptoms, possible risks and the safest treatment options.

Get SUNLENCA 464 mg INJECTABLE SOLUTION Prescription Online

1

Fill in a 2-min form

Tell us your symptoms, history, and what medicine you're requesting.

2

Pick a doctor or let us assign

Choose a specialist or we'll match you with the next available doctor.

3

Doctor reviews your case

Usually within 30 minutes. They may ask follow-up questions via chat.

4

Collect from any pharmacy

Electronic prescription sent to your email — valid across Spain.

Frequently Asked Questions

Is a prescription required for SUNLENCA 464 mg INJECTABLE SOLUTION?

SUNLENCA 464 mg INJECTABLE SOLUTION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.

What is the active substance in SUNLENCA 464 mg INJECTABLE SOLUTION?

The active ingredient in SUNLENCA 464 mg INJECTABLE SOLUTION is lenacapavir. This information helps identify medicines with the same composition but different brand names.

Who manufactures SUNLENCA 464 mg INJECTABLE SOLUTION?

SUNLENCA 464 mg INJECTABLE SOLUTION is manufactured by Gilead Sciences Ireland Unlimited Company. Pharmacy brands and packaging may differ depending on the distributor.

Which doctors can assess the use of SUNLENCA 464 mg INJECTABLE SOLUTION online?

Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether SUNLENCA 464 mg INJECTABLE SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.

How to buy SUNLENCA 464 mg INJECTABLE SOLUTION in Spain?

Spain has a well-developed healthcare infrastructure across major cities such as Madrid, Barcelona, Valencia, and Seville. Pharmacies are widely available and operate under strict regulations, ensuring access to prescribed medications.

You can buy SUNLENCA 464 mg INJECTABLE SOLUTION in Madrid, Barcelona, Seville, or Valencia at any local pharmacy with a valid prescription.

To obtain a prescription, you can use Oladoctor:

What are the alternatives to SUNLENCA 464 mg INJECTABLE SOLUTION?

Other medicines with the same active substance (lenacapavir) include SUNLENCA 300 mg FILM-COATED TABLETS, CELSENTRI 150 mg FILM-COATED TABLETS, CELSENTRI 300 MG FILM-COATED TABLETS. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.

bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media